Duloxetine,
does it really help with Patient-perceived pain reduction in painful diabetic peripheral neuropathy?
research showsDuloxetine reduces painful diabetic peripheral neuropathy but is rated C with 59 points because confirmatory evidence is concentrated in the manufacturer development program. In a 348-person intention-to-treat trial, 30% pain response occurred in 68.1% versus 43.4%, and the pooled odds ratio for 50% response was 2.06. The IMMPACT/Dworkin threshold of about 30% is a within-person definition of moderately important improvement, not a between-group mean-difference threshold.
ads claimClaims that duloxetine repairs neuropathy or eliminates pain for everyone exceed the evidence. Trials measured pain intensity and patient response, not structural recovery of injured peripheral nerves.
Useful facts when choosing a product
- The pivotal 12-week trial compared duloxetine 60 mg once or twice daily with placebo.
- IMMPACT recommendations interpret about 30% pain reduction as a moderately important improvement in chronic pain.
- Verdict 1703, which is C with 58 points, concerns fibromyalgia; verdict 774, which is B with 60 points, concerns major depressive disorder.
What the research actually shows
Raskin 2005 randomized 348 participants equally to duloxetine 60 mg once daily, 60 mg twice daily, or placebo and analyzed all 348 by intention to treat; overall attrition was reported as about 15%. Wu 2023 pooled seven trials and found pain MD -0.89 (95% CI -1.09 to -0.69) and OR 2.06 (1.67 to 2.54) for 50% response, but the large-effect judgment relies on responder outcomes rather than the mean difference alone. Of 18 trials in the Cochrane review, the only nonmanufacturer trial was Vranken 2011 in central neuropathic pain, not a confirmatory diabetic-neuropathy trial. All confirmed efficacy trials for this indication were therefore conducted within the manufacturer program.
Why this is classified as C (59)
The primary pain outcome and clinically important 30% and 50% responder outcomes were repeatedly positive, but all confirmed diabetic-neuropathy trials were manufacturer-program studies and Raskin 2005 had about 15% attrition, giving C with 59 points.
Counterpoint. Twice-daily 60 mg was not clearly more effective than once-daily dosing and produced more adverse-event discontinuations. Individual benefit and tolerability both matter.
Rejudgment record. Cross-check applied — Repeated success on pain and clinically important responder outcomes, tempered by manufacturer-only confirmatory evidence in diabetic neuropathy and approximately 15% attrition in the pivotal trial
| Endpoint | P | Patient-reported treatment goal - the symptom is the goal |
| Replication | R2 | Independently replicated across trials |
| Independence | I0 | Evidence comes only from manufacturer studies |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Reduced mean 24-hour pain | C | The primary endpoint succeeded at P<0.001 in 348 participants, but this was a manufacturer trial. |
| Increased probability of at least 30% pain response | C | Response was 68.1% with 60 mg once daily versus 43.4% with placebo. |
| Increased probability of 50% pain response | C | The pooled odds ratio across seven randomized trials was 2.06. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Raskin J et al. 2005 | Multicenter randomized double-blind placebo-controlled trial | 15 | Eli Lilly development trial; multiple authors were affiliated with Lilly Research Laboratories | Weekly mean 24-hour average pain score over 12 weeks | Change was -2.72 with 60 mg once daily versus -1.39 with placebo, P<0.001, so the primary endpoint succeeded; 30% response was 68.1% versus 43.4%. | Pivotal manufacturer trial |
| Wu CS et al. 2023 | Systematic review and meta-analysis | 7 | Authors reported no specific funding and no conflicts; included trials were manufacturer-centered | Pain improvement, 50% pain response, and quality of life | Pain MD -0.89 (95% CI -1.09 to -0.69) and OR 2.06 (1.67 to 2.54) for 50% response. | Pooled replication that does not create trial-funding independence |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-24).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Duloxetine x pain reduction in diabetic peripheral neuropathy — Evidence Grade C·59. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/general/duloxetine-painful-diabetic-peripheral-neuropathy/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.